Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR1 | P30989 | 15/20 | 0.56 |
| ▸ | NTSR2 | O95665 | 13/20 | 0.56 |
| ▸ | NPY1R | P25929 | 2/20 | 0.55 |
| ▸ | NPY2R | P49146 | 1/20 | 0.55 |
| ▸ | NPY4R | P50391 | 1/20 | 0.55 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.55 |
| ▸ | SORT1 | Q99523 | 10/20 | 0.53 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.51 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.51 |
| ▸ | OXTR | P30559 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31556390 | 0.95 | NTSR1 (0.56) | NTSR1NTSR2NPY1RNPY2RNPY4R | |
| SCHEMBL29496648 | 0.91 | NTSR1 (0.69) | NTSR1NTSR2NPY1RNPY2RNPY4R | |
| SCHEMBL29420245 | 0.91 | NPY1R (0.64) | NTSR1NTSR2NPY1RNPY2RNPY4R | |
| SCHEMBL14060698 | 0.89 | NPY1R (0.55) | NTSR1NTSR2NPY1RNPY2RNPY4R | |
| SCHEMBL29377200 | 0.89 | NTSR1 (0.61) | NTSR1NTSR2NPY1RNPY2RNPY4R | |
| SCHEMBL29612082 | 0.88 | NPY1R (0.62) | NTSR1NTSR2NPY1RNPY2RNPY4R | |
| SCHEMBL20707335 | 0.88 | NPY1R (0.62) | NTSR1NTSR2NPY1RNPY2RNPY4R | |
| SCHEMBL29612065 | 0.88 | NPY1R (0.62) | NTSR1NTSR2NPY1RNPY2RNPY4R | |
| SCHEMBL29611524 | 0.88 | NPY1R (0.62) | NTSR1NTSR2NPY1RNPY2RNPY4R | |
| SCHEMBL29612137 | 0.88 | NPY1R (0.62) | NTSR1NTSR2NPY1RNPY2RNPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3773497-B1 | OXYTOCIN COMPOSITIONS AND METHODS OF USE | ELGAN PHARMA LTD (IL) | 2023-10-18 | — | — | EP | disclosed |
| US-11414459-B2 | Metabolite inspired selective oxytocin receptor agonists | Kinoxis Therapeutics Pty Ltd (AU) | 2022-08-16 | — | — | US | disclosed |
| US-11266711-B2 | Oxytocin compositions and methods of use | ELGAN PHARMA LTD (IL) | 2022-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11414459-B2 | Metabolite inspired selective oxytocin receptor agonists | OXTR, AVPR2, AVPR1A | NTSR1 31/4885NTSR2 37/4885NPY1R 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.